ATE361993T1 - Diagnose und behandlung von prostatakrebs - Google Patents

Diagnose und behandlung von prostatakrebs

Info

Publication number
ATE361993T1
ATE361993T1 AT01960979T AT01960979T ATE361993T1 AT E361993 T1 ATE361993 T1 AT E361993T1 AT 01960979 T AT01960979 T AT 01960979T AT 01960979 T AT01960979 T AT 01960979T AT E361993 T1 ATE361993 T1 AT E361993T1
Authority
AT
Austria
Prior art keywords
hne
gated
voltage
nucleic acid
cancer
Prior art date
Application number
AT01960979T
Other languages
English (en)
Inventor
Mustafa Djamgoz
Scott Fraser
James Diss
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Application granted granted Critical
Publication of ATE361993T1 publication Critical patent/ATE361993T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01960979T 2000-09-02 2001-09-03 Diagnose und behandlung von prostatakrebs ATE361993T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0021617.6A GB0021617D0 (en) 2000-09-02 2000-09-02 Diagnosis and treatment of cancer

Publications (1)

Publication Number Publication Date
ATE361993T1 true ATE361993T1 (de) 2007-06-15

Family

ID=9898761

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01960979T ATE361993T1 (de) 2000-09-02 2001-09-03 Diagnose und behandlung von prostatakrebs

Country Status (10)

Country Link
US (2) US20060166194A1 (de)
EP (1) EP1313882B1 (de)
JP (1) JP2004507254A (de)
AT (1) ATE361993T1 (de)
AU (1) AU2001282364A1 (de)
CY (1) CY1107715T1 (de)
DE (1) DE60128368T2 (de)
ES (1) ES2288979T3 (de)
GB (1) GB0021617D0 (de)
WO (1) WO2002018637A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393657B2 (en) * 2001-04-12 2008-07-01 Imperial College Innovations Limited Diagnosis and treatment of cancer: I
AU2002251286A1 (en) * 2001-04-12 2002-10-28 Imperial College Innovations Limited Diagnosis and treatment of cancer:ii
WO2005069969A2 (en) * 2004-01-21 2005-08-04 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
JP5422120B2 (ja) * 2004-05-27 2014-02-19 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト 癌患者による上皮成長因子受容体阻害薬に対する臨床転帰の予測方法
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
EP2029779A4 (de) 2006-06-14 2010-01-20 Living Microsystems Inc Verwendung hoch paralleler snp-genotypisierung zur fötalen diagnose
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
BRPI0817393A2 (pt) * 2007-11-19 2015-03-31 Genentech Inc Anticorpo monoclonal, polipetídeo solúvel isolado, método de inibição do progresso de tumores, método de inibição de emt em células e método de determinação se um tumor reagirá a um antagonista de b2 ou um antagonista de notch
GB0811360D0 (en) * 2008-06-20 2008-07-30 Imp Innovations Ltd Methods
WO2010033578A2 (en) 2008-09-20 2010-03-25 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US20120283116A1 (en) 2009-09-11 2012-11-08 Leppert Mark F Mutant Sodium Channel Nav1.7 and Methods Related Thereto
PH12013501865A1 (en) 2011-03-16 2014-01-06 Amgen Inc Potent and selective inhibitors of nav1.3 and nav1.7
US9636418B2 (en) 2013-03-12 2017-05-02 Amgen Inc. Potent and selective inhibitors of NAV1.7
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
CN112513273A (zh) 2018-06-22 2021-03-16 豪夫迈·罗氏有限公司 用于调节scn9a表达的寡核苷酸

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2204355C (en) * 1994-11-02 2001-01-16 Gail Mandel Peripheral nervous system specific sodium channels, dna encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof
US7399599B2 (en) * 2000-07-10 2008-07-15 Vertex Pharmaceuticals (San Diego) Llc Ion channel assay methods

Also Published As

Publication number Publication date
DE60128368T2 (de) 2008-01-10
DE60128368D1 (de) 2007-06-21
ES2288979T3 (es) 2008-02-01
GB0021617D0 (en) 2000-10-18
CY1107715T1 (el) 2013-04-18
EP1313882A2 (de) 2003-05-28
JP2004507254A (ja) 2004-03-11
EP1313882B1 (de) 2007-05-09
WO2002018637A2 (en) 2002-03-07
US7759078B2 (en) 2010-07-20
US20060166194A1 (en) 2006-07-27
AU2001282364A1 (en) 2002-03-13
WO2002018637A3 (en) 2002-11-21
US20080145859A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
DE60128368D1 (de) Diagnose und behandlung von prostatakrebs
WO2002083945A3 (en) Diagnosis and treatment of cancer: i
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
DE60134995D1 (de) Verfahren und zusammensetzungen, die eine stearoyl-coa desuturase-hscd5 verwenden
DE69933989D1 (de) Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
WO2000052054A3 (en) Antibodies for cancer therapy and diagnosis
WO2004110345A3 (en) Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
WO2002046222A3 (en) Compositions and methods for diagnosing alzheimer's disease
EP1004022A4 (de) Methoden und zusammensetzungen zum überwinden der resistenz gegen bio- und chemotherapie
DE60028544D1 (de) Prostata-spezifische gene zur diagnose, prognose und behandlung von prostata-krebs
WO2000009754A3 (en) HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS
ATE375389T1 (de) Verfahren zur diagnose, prognose und behandlung von glaukom und verwandten erkrankungen
BRPI0407213A (pt) Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados
BR0312483A (pt) Anticorpos e seus usos
DE69920681D1 (de) Humaner k+ ionenkanal und therapeutische verwendungen davon
Schoser et al. A large german kindred with cold‐aggravated myotonia and a heterozygous A1481D mutation in the SCN4A gene
Buduneli et al. Plasminogen activators and plasminogen activator inhibitors in gingival crevicular fluid of cyclosporin A‐treated patients
DE60225845D1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie
WO2001090156A3 (en) Card domain containing polypeptides, encoding nucleic acids, and methods of use
DE60035857D1 (de) Nukleinsäure- und aminosäuresequenzen von durch hämoglobin induzierbaren genen aus candida albicans und die verwendung dieser sequenzen in reagenzien zur diagnose von disseminierten candida albicans infektionen
WO2001016158A3 (en) Bridging integrator-2 (bin2) nucleic acid molecules and proteins and uses therefor
ATE397090T1 (de) Verfahren und verbindungen zur diagnose von entzündlichen erkrankungen und identifizierung von pharmakologischen mitteln zur behandlung von entzündlichen erkrankungen
WO2003084480A3 (en) HAUSP-p53 INTERACTION AND USES THEREOF

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties